UpcomingPDUFA target action date

Relutrigine

Praxis Precision Medicines (PRAX)

Marketer take

Rare pediatric epilepsy launch where genetic testing and epileptologist outreach drive patient finding.

Sponsor company
Praxis Precision Medicines (PRAX)
Indication
SCN2A and SCN8A developmental and epileptic encephalopathies (DEE)
Therapeutic area
Neurology, Rare disease
Event
PDUFA target action date
Date
Dec 27, 2026
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move